Drug Trial Radar · NCT01842607
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
Last checked: Nov 20, 2026Latest source record: Aug 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
651
Actual
Start
May 27, 2013
Primary completion
Mar 13, 2015
Study completion Mar 13, 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study.
Conditions
- Asthma
Interventions
MepolizumabBiological
Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunoglobulin (Ig)E-mediated and Non-allergic) and Local Site ReactionsTime frame: From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-last dose])
Locations
137 sites in 19 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
Rolling Hills Estates, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Albany, Georgia
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Rochester, Minnesota
GSK Investigational Site
New York, New York
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Durham, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Hershey, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Salt Lake City, Utah
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Mendoza, Argentina
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina
GSK Investigational Site
San Rafael, Mendoza Province, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
GSK Investigational Site
New Lambton, New South Wales, Australia
GSK Investigational Site
Bedford Park, South Australia, Australia
GSK Investigational Site
Clayton, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Liège, Belgium
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.